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Abstract
Papillomavirus is an oncogenic virus which infects mucosal and cutaneous epithelia
where it induces benign hyperproliferative lesions. Few studies have been conducted
on the causative factors associated with the development of cancer. Infections by high-
risk human papillomaviruses (HPVs) have been implicated as causative agents in a
variety of cancers such as anogenital, and head and neck cancers. HPVs appear to have
evolved mechanisms resulting in escape from host immune surveillance and delay of
resolution of infection. The HPV E5 oncoprotein is one of the possible effectors that
allows the virus to escape from host immune system through the downregulation of
surface  classical  major  histocompatibility  complex  class  I  (MHC  I)  and  not  the
nonclassical MHC I. Lack of classical MHC I in infected cells expressing E5 would allow
evasion  of  cytotoxic  T  lymphocytes  (CTLs)  killing  and  thus  establishment  and
persistence of viral infection.
In this chapter we discuss the process of immunomodulation by HPV and review our
recent  discoveries  on  the  association  of  HPV  with  cancers  and  its  implication  in
medicine.
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1. Introduction
The global cancer burden is markedly increasing and is thus a leading cause of death, second
only to cardiovascular disease [1–3]. Based on the most recent available data collected by the
international agency for cancer, an estimated 14.1 million new cancer cases and 8.2 million
cancer-related deaths occurred in 2012, compared with 12.7 million and 7.6 million, respec‐
tively, in 2008 [4].
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The human body is dependent on regulated cell division and elimination which forms
homeostasis within the body. Certain genes play vital roles in regulating the cell cycle. These
genes are grouped into three categories, tumour suppressor genes (TSGs), proto-oncogenes
and DNA repair genes. Any alteration in these groups of genes downregulates the cell control
mechanisms and ultimately causes cancer cell development and malignant transformation [5].
Genetic changes in the progression of cancer typically affect two different types of genes,
oncogenes (e.g., Ras) and TSGs (e.g., P53 and pRB). Both of the oncogenes and TSGs encode
many kinds of proteins that play a key role in cancer induction. These genes control cell growth
and proliferation, and mutations in these genes can contribute to the development of cancer.
Despite of the evolving medical significance of cancers, few studies have been conducted to
identify the possible risk factors that implicated in the initiation of cancer. However, there are
well-established risk factors that have been identified for its association with the development
of cancer such as clinical, genetic and epidemiological factors. In addition, biological agents
have been implicated in various cancers including viruses, bacteria and parasites.
Viruses have been the most studied in their relation to tumour formation. They are thought to
be associated with 15–20% of all human cancers worldwide of which about 80% are cancers of
the cervix and liver [6, 7]. Viruses have evolved multiple strategies to transform host cell. One
common route is to alter the expression of cellular genes by integration of the viral genome
into the cellular DNA. Viruses also help cause malignancy by introducing an oncogene into a
cell to disrupt the regulation of cell division [8–10].
Infectious agents have been implicated, either as direct carcinogens or as promoters. Viral
infections, in particular, human papillomaviruses (HPVs) are recognised as carcinogenic
agents in humans and are responsible for a significant share of the global cancer burden [7, 11,
12].
HPVs are small double-stranded DNA oncogenic viruses of approximately 8 kbp. HPVs are
ubiquitous in the human population, and occasionally infection leads to cervical cancer.
Although the body is working to get the infection under control, HPVs infect and disturb
cutaneous and mucosal epithelial cells of the anogenital tract, hands or feet which can lead to
a variety of diseases with a range of severities depending on the types of HPV infection.
To date, over 100 different types of HPV have been identified, and about one-third of these
infect epithelial cells in the genital tract. The type HPV family is divided into two categories:
low-risk HPVs and high-risk HPVs (HR-HPVs). The low-risk HPV types such as HPV 6 and
HPV 11 commonly cause benign genital warts (condylomas). These lesions can regress even
without treatment [13], due to cell-mediated immune responses [14]. While the high-risk types
of HPV which include HPV 16, 18, 31, 35 and 45 are associated with the development of
anogenital cancers and found in up to 99% of all cervical carcinomas [15, 16]. These HR-HPV
types cause benign genital epithelial hyperproliferative lesions, such as low-grade premalig‐
nant cervical intraepithelial neoplasia (CIN I). In most premalignant cases, lesions can regress
even without treatment. However, in a limited number of cases, the lesions persist or progress
to invasive cancer due to the lack or ineffective immunological responses.
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It has been reported that the low-grade CIN I would progress to high-grade lesion (CIN III)
and eventually invasive cervical cancer [17]. Consequently, the associations of the HPV
infection in the development of cancer are an area of ongoing interest.
2. The host immune evasion by HPV
The papillomaviruses are small double-stranded DNA viruses which belong to the papillo‐
maviridae family [6]. HPVs infect cutaneous or mucosal epithelial cells initiating benign or
cancerous lesions that depend on the HPV types. The lifecycle, oncogenic characteristics and
molecular-based evidence of HR-HPVs are suggestive of a causal role for cancer. HPV
infections are normally cleared by the immune system; however, the persistence of HPV could
trigger a progression to malignant lesion in the presence of other risk factors. For instance, it
is well documented that the persistent infection of the cervix with HR-HPV types 16 and 18 is
an initiating event of the cervical cancer [18, 19]. Therefore, the establishment, persistence of
HR-HPV infection and evasion of the host immune system are necessary for premalignant
lesions to initiate and progress towards squamous carcinoma [20–22].
The host immune response mechanism plays a significant role in controlling and limiting HPV
infection. The suppression of HPV-induced lesion depends on the host inflammatory reaction
and penetration of lymphocytes to the infected tissue [14]. Thus, the prevalence of HPV-
induced lesions is higher in immunosuppressed individuals such as transplant recipients or
human immunodeficiency virus (HIV)-infected patients [23, 24].
Lack of HPV clearance and persistence of viral infection for many months are necessary before
the onset of an immune response. The reasons of this fact are still unknown. And perhaps one
of the most important ongoing questions in the field of papillomavirus research is the latency
of the host immune response in eliminating the virus in immunocompetent hosts as well as
immunosuppressed hosts.
The nonlytic feature of HPV is one of the explanations for evading the recognition of HPV
infection. HPV does not lyse the infected cell or cause viremia, and this will reduce the exposure
of viral antigen to cell-mediated immunity and consequent lack of inflammation. HPV life
cycle characterised by the physical evasion from the immune cells’ recognition through HPV
restoration and protection within infected cells’ nuclei [25, 26]. Additionally, HPV has the
ability to downregulate major histocompatibility complex class I (MHC I) and disrupt the
interferon (IFN) pathway. HPV facilitates this mechanism using early oncoproteins, E5, E6 and
E7, which have the ability to interfere and actively participate to the downregulation of host
immune system. The role of E6 and E7 is to inhibit the production of IFN in natural killer (NK)
cells or the expression of transporter associated with antigen processing (TAP) [27, 28].
E5 oncoprotein downregulates surface MHC class I by retaining it in the Golgi apparatus
(Figures 1 and 2) [20, 29]. Downregulation of MHC class 1 has been observed with E5 from
different PVs, including HPV-85 and HPV-16 (Figure 3), indicating that key functions of E5
are conserved between the PV species and HPV types [21].
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Figure 1. The expression of MHC I in control and transformed PalF cells using Define FACS as “Fluorescence-activated
cell sorting” (A and B), control cells (C and D), 4-E5 transfected cells (E and F) and 1-E5 transfected cells (G and H)
were incubated with anti MHC 1 antibody. Surface MHC I (A, C, E and G) and total MHC I (B, D, F and H) [29].
Figure 2. Visualisation of the GA and MHC I. HaCaT cells carrying empty vectors or cells expressing HPV-16 E5
were costained with anti-HLA class I antibody (mAb W6/32) and anti-golgi GM130 antibody (mAb 4A3) and analysed
using Leica TCS SP2 fluorescence confocal microscopy. Representative cells are shown. (A) Control HaCaT cells carry‐
ing either pcDNA or pL2 empty vector. (B) HeCaT cells expressing HPV-16 E5 in either pcDNA (pc-16E5) or pL2
(pL2-16E5). N = nucleus [20].
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Figure 3. Total and surface expression of MHC-I using FACS analysis in normal HaCaT cells transfected with pcDNA
(empty vectors), pcHPV16E5, HPV83-E5a (antisense orientation) and HPV83-E5s (sense orientation) [21].
E5 is the smallest HPV oncogenic protein that is located in the membranes of the endoplasmic
reticulum (ER) and Golgi apparatus of the transformed cells. This hydrophobic protein is a
structure of 83 amino acids in HR-HPV type 16, is expressed before the onset of viral replica‐
tion. E5 contribute to cell transformation through interaction with several cellular proteins,
including the epidermal growth factor receptor (EGF-R), the human receptor for colony
stimulating factors (CSF-1). E5 may also reduce the processing and presentation of viral antigen
through the interaction with 16 kDa subunit of the vacuolar H+-ATPase acidification of
endosome [30].
The human MHC class I molecules are known as human leukocyte antigen (HLA) system,
which have a critical function in the recognition of virally infected cells. The proteasomes and
other cytoplasmic proteases are playing a role in viral protein degradation into short chain
peptides of 8–10 amino acids long. HLA molecules and intracellular viral antigenic peptides
complex are transported through the Golgi apparatus to the cell surface of infected cells where
it is presented and recognised by the cytotoxic CD8+ T cells. The activated cytotoxic T lym‐
phocytes (CTLs) are able to destroy the infected cell through the mechanism of apoptosis that
mediated either by granulate exocytosis (perforin and granzymes) or by Fas-Fas ligand
interaction [26].
High frequency of virus-specific CTLs is a characteristic of persistent viral infection such as
cytomegalovirus (CMV) and Epstein-Barr virus (EBV), however low frequency of HPV-
specific CTL has been detected in CIN III and cervical cancer patients [31, 32].
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CD4+ T helper lymphocytes (Ths) are able to identify foreign antigens that presented on MHC
class II molecules (antigen-MHC II complex). MHC class II molecules are mostly expressed on
professional antigen presenting cells (APCs) such as dendritic cells, macrophages and B cells,
but they can also be expressed on the epithelial cells (target for HPV) by IFN treatment.
T helper cells are capable of secreting cytokines that allow the proliferation and maintenance
of cytotoxic lymphocytes. Additionally, they play a role in activation of B cells for antibody
production, as well as dendritic cells for antigen presentation. Th cells potentially have an
important role in cell-mediated immunity against HPV infection. The reactivity of HPV-
restricted Th cells was found in patients with a persistent papillomavirus infection [33, 34].
While E6 and E7 are presented throughout the course of the HPV infection, their functions are
necessary for the maintenance of a transformed status. Expression of E5 takes place in the early
stage of papillomavirus infection and in the deep layers of the infected epithelium. Ashrafi et
al. [29] were the first to report that E5 protein of HPV downregulates the classical HLA (A and
B) but not the nonclassical HLA-E. This potentially allows the cell to escape CTL and also NK
cells’ killing [20].
The downregulation of MHC class I by E5 oncoprotein allows the infected cell to evade cell-
mediated immune response and this potentially enables other HPV oncoproteins in the
establishment and persistence of virus infection. Interestingly, it has been reported that the
oncogenic E5 also inhibits the Fas receptor [35] and HLA II [36]. This strongly indicates that
E5 might have additional major role in negatively regulating the immune response.
The downregulation of MHC I is an imperative mechanism to evade CTL-mediated immune
clearance, however, the lack of surface MHC I will activate NK cells to attack and destroy the
infected cells. Human NK cells express surface receptors (NKRs) that interact with HLA class
I molecules, including killer cell immunoglobulin-like receptors (KIRs) that mainly recognise
classical HLA-C and also C type lectin receptors which identify nonclassical HLA-E molecule.
In the absence of classical HLA-C and non-classical HLA-E, NK-mediated cell lysis would be
inhibited due to the recognition of MHC class I molecules by their inhibitory receptors.
Consequently, certain viruses, including HIV and CMV, have the ability to escape both CTL
and NK cells’ killing. HIV-negative proteins (Nef) and CMV US3/UL40 proteins have evolved
to selectively downregulate HLA (A and B), the main presenters of peptides to CTLs, but not
HLA-C or nonclassical HLA-E [37, 38].
3. HR-HPVs and cancers
HR-HPV types are considered as the most important aetiological factors for many types of
cancers such as cervical cancer. The risk of cervical cancer has increased in parallel with the
incidence of certain genotypes of HR-HPV. Therefore, the presence of these genotypes
indicates a significant risk factor for the initiation and progression of almost 90% of cervical
cancer cases [18].
Despite the medical significance of HR-HPV infection, there is still a lack of information on
the incidence of cancers that are caused by different HR-HPV genotypes in different popula‐
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tions. An investigation on the incidence and distribution of HR-HPV genotypes in cervical
cancer patients confirmed the presence of additional high-risk types (HPV-45 and HPV-39)
other than common types (HPV-16 and HPV-18) [19].
Being a sexually contagious virus, HPV virus has the ability to spread through sexual and skin-
to-skin contact. HR-HPVs have also been found to be the causative agents for almost up to half
of vaginal, penile, anal and oral cancers. These findings suggest that HR-HPV virions might
be spread from the original infected site to other organs and lead to cancer development in
various organs [18].
To date, studies on the role of HPV in breast carcinogenesis have generated considerable
controversies and it is still not clear whether HPV infection is implicated in breast cancer
pathogenesis [39]. HPV infection is a sexually transmissible disease, and most breast cancers
originate from mammary duct epithelia. Therefore, the relationship between HPV and breast
cancer is imperative for many reasons. The exposure of the mammary ducts to the external
environment increases the risk of HPV infection. Our unpublished data have shown the
presence of HR-HPV types of viral DNA other than 16 and 18 in freshly collected human breast
cancer tissue and this provides a solid basis to advance research in a crucial health problem
affecting women.
These initial findings support the association of HPV and breast cancer and highlight possible
causative agents of breast cancer. Therefore, further research is required to investigate whether
HR-HPV infection plays a role in the pathogenesis of breast cancer. The information gained
will pave the way to better awareness of breast cancer risk factors other than those recognised
to date.
4. Conclusions
Identification of HPV pathogenesis offers means of therapeutic intervention targeted against
HPV oncoproteins (E5, E6 and E7) which will facilitate early lesion eradication. This will also
provide results central to our understanding of HPV pathogenesis and help elucidate early
events in HPV infection that may determine persistence and disease development.
Moreover, our findings on the presence of high-risk HPV-39 and HPV-45 types in cervical
cancer other than types 16 and 18 [19] and the presence of different types of HR-HPV in breast
cancer will postulate a need for further assessment of the influence of current prophylactic
vaccination programs that is protective against the two most common oncogenic papilloma‐
viruses, HPV-16 and HPV-18, but not against other high-risk mucosal HPVs detected in our
studies.
Viral carcinogenesis and cancer prevention are rapidly developing sectors of this field, and the
future translation of this chapter lead to a faster resolution of HPV infection, and with obvious
advantages for all HPV-affected patients, and in particular for individuals affected by early
HPV-related cancer diseases.
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